United Therapeutics saw its IBD SmartSelect Composite Rating jump to 96 Thursday, up from 94 the day before.
The new score indicates the company is now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria.
United Therapeutics is currently forming a consolidation, with a 417.81 buy point. See if the stock can break out in heavy trade at least 40% higher than normal.
Discover The 3 Keys To Successful Stock Investing
The stock earns a 90 EPS Rating, which means its recent quarterly and longer-term annual earnings growth is outpacing 90% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q3, the company reported 19% earnings growth. Sales growth increased 23%, up from 20% in the prior quarter. That marks one quarter of increasing revenue gains. The company's next quarterly report is expected on or around Feb. 19.
United Therapeutics holds the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals is the No. 1-ranked stock within the group.
